ArticleThe Journal of clinical investigation2022

An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.

Meijie Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.